Lorati claims breakthrough treatment for AIDS

14 July 2015

Taiwan-based biotechnology firm Lorati says it has found a nano-medication based treatment for AIDS. The company said it has successfully developed nano-medication, based on bentonite, which can effectively curtail the replication of HIV-1 virus.

The company said the treatment has been effective in curtailing the growth of the virus, adding that a few months of treatment for AIDS patients can revert their status to HIV-1. Further, the treatment does not cause any side effects, Lorati claims.

Lorati chief executive David Lo said no existing drug or medication has been able to treat HIV-1 in the brain, adding that nano-medication can overcome the barrier as evidenced in the successful treatment of brain cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >